We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of United ...

Coming in No. 3 on Fast Company's Queer 50 list, is Martine Rothblatt, the founder and CEO of United Therapeutics. She's also a lawyer, satellite entrepreneur, and futurist. See the innovative ...

United Therapeutics is down 11.5% since the beginning of the year, and at $318.89 per share, it is trading 22.2% below its 52-week high of $410 from November 2024.

Shares of United Therapeutics fell on pace for the largest percent decrease in three years after the company's fourth-quarter earnings fell short of expectations. The stock was down 10% ...

UNITED THERAPEUTICS ($UTHR) posted quarterly earnings results on Wednesday, February 26th. The company reported earnings of $6.19 per share, missing estimates of $6. ...

Shares of United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, MarketBeat reports.

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by ...

In trading on Wednesday, shares of United Therapeutics Corp (Symbol: UTHR) entered into oversold territory, hitting an RSI reading of 28.5, after changing hands as low as $319.02 per share.